

**Table S1.** Coagulation, cytokine levels, and lymphocyte analysis 24 h after LPS challenge

	No LPS	LPS	LPS/APC	LPS/360A
Blood coagulation markers				
Platelet counts (10 <sup>3</sup> /μl)	451.7 ± 46.1	214.2 ± 55.2	147.3 ± 120.6	116.3 ± 51.2
Hematocrit %	40.3 ± 3.1	40.7 ± 4.7	41.7 ± 4.9	43.8 ± 4.0
Fibrinogen (mg/ml)	1.26 ± 0.46	6.24 ± 1.53	6.32 ± 1.55	6.69 ± 1.72
D-dimer (ng/ml)	300.8 ± 74	716.8 ± 174.1	456.3 ± 214.1*	777.5 ± 157.4
Cytokines (pg/ml)				
IL-1	81.1 ± 55.9	3,261.3 ± 789.3	2,988.8 ± 1,161.4	3,572.8 ± 546.2
IL-1	113.4 ± 8.3	980.4 ± 109.3	858.7 ± 165.7	847.9 ± 98.2
IL-2	12.3 ± 4.2	75.5 ± 7.7	79.6 ± 16.6	75.8 ± 9.9
IL-3	9.2 ± 3.6	ND	ND	ND
IL-4	11 ± 4.4	31 ± 11	15.2 ± 3.4	22.6 ± 2.9
IL-5	19.8 ± 9.1	83 ± 21.7	57.3 ± 21.7	63.9 ± 18.5
IL-6	49.1 ± 11.7	5,704.5 ± 5,928	4,837.5 ± 7,372.9	2,249.2 ± 3,248.9
IL-9	572 ± 467	ND	ND	ND
IL-10	310.7 ± 170.4	1,917.6 ± 101.2	1,294.2 ± 400.4	1,473.2 ± 309.9
IL-12p40	531.5 ± 216.9	7,265.9 ± 3,126	3,953.3 ± 3,393.5	3,105.2 ± 1,502.5
IL-12p70	289.7 ± 185.1	1,204 ± 329	632.5 ± 210.4	758.7 ± 134
IL-13	341.6 ± 225.6	785.7 ± 112	779.2 ± 126.4	773.9 ± 104.3
IL-17	121.7 ± 54.4	604.6 ± 381	258.5 ± 215.5	210.8 ± 91.1
Eotaxin	855.2 ± 243	12,544.5 ± 233.9	10,914.8 ± 926.4	11,462.1 ± 301
G-CSF	145.8 ± 35.5	50,353.8 ± 17,461	31,136.9 ± 14,942.3	40,054.1 ± 11,340
GM-CSF	135.1 ± 30.2	471.5 ± 117.1	280.8 ± 52.8	342.5 ± 111.7
IFN-	84 ± 14.9	366.4 ± 88.1	250.6 ± 59.7	307.1 ± 131.3
KC	22.43 ± 6.8	7,457.5 ± 2,541.7	2,551.8 ± 2,653.5	5,164.9 ± 2,252.7
MCP-1	305.7 ± 71.3	13,354 ± 15,028.3	9,491.4 ± 11,352.3	6,032.1 ± 3,375.4
MIP-1	332.8 ± 244	2,164.7 ± 195.4	1,924.6 ± 558.1	1,877.7 ± 308.9
MIP-1	51.2 ± 27.8	678.1 ± 229.3	567.1 ± 155.1	540.5 ± 46.4
RANTES	200.3 ± 153.6	5,164.5 ± 2,037.4	4,841 ± 1,885.5	4,923.2 ± 1,149.6
TNF-	963 ± 317.1	5,917.6 ± 1,712.2	4,323.7 ± 1,546.7	4,443.4 ± 1,157.4
Blood cell counts (% and 10 <sup>3</sup> /μl)				
Lymphocytes	52.6 ± 6.5/1.9 ± 0.82	20.9 ± 7.4/0.67 ± 0.59	27.2 ± 8.5/1.22 ± 0.61	24.7 ± 7.2/1.38 ± 0.51
Monocytes	10 ± 0.9/0.37 ± 0.22	7.1 ± 0.9/0.2 ± 0.15	7.2 ± 0.6/0.27 ± 0.13	7.1 ± 1.3/0.4 ± 0.19
Granulocytes	37.7 ± 7.4/1.32 ± 0.41	72 ± 8.2/2.25 ± 1	65.5 ± 9/3.7 ± 1.08	68.3 ± 8.2/3.98 ± 1.92
FACS analysis on spleen tissue (% and 10 <sup>6</sup> cells)				
T lymphocytes				
CD4 <sup>+</sup>	20.8 ± 3.7/1.04 ± 0.19	12.5 ± 1/0.63 ± 0.5	12.9 ± 2.4/0.65 ± 0.12	ND
CD8 <sup>+</sup>	18.9 ± 3.2/0.45 ± 0.16	7.7 ± 1.8/0.39 ± 0.9	8.8 ± 2.1/0.44 ± 0.11	ND
CD3 <sup>+</sup>	32.7 ± 2.3/1.64 ± 0.12	18.3 ± 1.8/0.92 ± 0.9	18 ± 3/0.9 ± 0.15	ND
NK lymphocytes				
NK1.1 <sup>+</sup>	9.4 ± 4.6/0.47 ± 0.23	3.6 ± 2.2/0.18 ± 1.1	3.8 ± 0.4/0.19 ± 0.02	ND
B lymphocytes				
B220 <sup>+</sup>	51.5 ± 5.8/2.58 ± 0.29	54.5 ± 20.7/2.73 ± 1.04	43.1 ± 7.6/2.16 ± 0.38	ND
Granulocytes				
GR1 <sup>+</sup>	3.5 ± 0.7/0.18 ± 0.04	14.6 ± 9.6/0.73 ± 0.48	22.7 ± 8.1/1.14 ± 0.41	ND
Monocytes				
Mac-1 <sup>+</sup>	2.7 ± 0.5/0.14 ± 0.03	12.7 ± 8.3/0.64 ± 0.42	20.8 ± 7.8/1.04 ± 0.39	ND

All collections were performed 24 h after LPS challenge/APC treatment. No significant difference was observed between cytokine groups after multivariate testing. \*, P ≤ 0.05 using the Student's *t* test. ND, not determined.

**Table S2.** Cytokine levels 3 h after LPS challenge in survivors (APC treated) and nonsurvivors (PBS treated)

Cytokines (pg/ml)	No LPS	LPS	LPS/APC
IL-1	81.1 ± 55.9	3,562.9 ± 1,803	3,660 ± 1,540
IL-1	113.4 ± 8.3	1,117 ± 315	1,013.2 ± 162.9
IL-2	12.3 ± 4.2	91.9 ± 46.5	71.2 ± 27.1
IL-3	9.2 ± 3.6	69.7 ± 15.5	57.2 ± 10.3
IL-4	11 ± 4.4	24.4 ± 11	21.5 ± 5.3
IL-5	19.8 ± 9.1	88.8 ± 27.7	62 ± 21.1
IL-6	49.1 ± 11.7	166,695 ± 209,070	192,593 ± 225,056
IL-9	572 ± 467	758.7 ± 238.5	723.7 ± 158.7
IL-10	310.7 ± 170.4	1,987.4 ± 670	2,997.2 ± 1,970.1
IL-12p40	531.5 ± 216.9	79,240.6 ± 39,668	36,693 ± 16,229
IL-12p70	289.7 ± 185.1	773.2 ± 192.5	526.3 ± 121
IL-13	341.6 ± 225.6	1,512.6 ± 229	1,396 ± 248
IL-17	121.7 ± 54.4	269.3 ± 61.8	156.3 ± 77.1
Eotaxin	855.2 ± 243	30,519.5 ± 22,554.8	18,481 ± 11,685
G-CSF	145.8 ± 35.5	2,067,251 ± 5,471,007	942,169.7 ± 2,270,567
GM-CSF	135.1 ± 30.2	384.7 ± 40.1	330.1 ± 42.7
IFN- $\gamma$	84 ± 14.9	319.8 ± 70.3	231 ± 51.3
KC	22.43 ± 6.8	44,650.5 ± 17,876	41,766 ± 16,178
MCP-1	305.7 ± 71.3	470,609 ± 367,985	242,488 ± 158,433.8
MIP-1	332.8 ± 244	6,441.8 ± 4,225.8	6,242.4 ± 3,738
MIP-1	51.2 ± 27.8	39,494 ± 22,443	51,402 ± 24,359
RANTES	200.3 ± 153.6	14,450 ± 6,187	9,559.3 ± 3,579
TNF-	963 ± 317.1	4,351.3 ± 711.8	3,623 ± 795.7

All collections were performed 3 h after LPS challenge/APC treatment. No significant difference was observed between cytokine groups after multivariate testing.

**Table S3.** Coagulation, cytokine levels, and lymphocyte analysis 24 h after LPS challenge in EPCR<sup>+</sup> and PAR1<sup>-/-</sup> mice

	WT Mice/LPS	WT Mice LPS/APC	EPCR <sup>+</sup> LPS	EPCR <sup>+</sup> LPS/APC	Par1 <sup>-/-</sup> LPS	Par1 <sup>-/-</sup> LPS/APC
Blood coagulation markers						
Platelet counts (10 <sup>3</sup> /μl)	214.2 ± 55.2	147.3 ± 120.6	171.2 ± 72.7	120 ± 50.6	179 ± 51.6	212.7 ± 76.6
Hematocrit (%)	40.7 ± 4.7	41.7 ± 4.9	40.5 ± 2.5	43.5 ± 4.5	43.3 ± 4.5	41.5 ± 4.6
TAT (g/L)	32.1 ± 31.9	18.9 ± 13.4	40.1 ± 17.8	53.7 ± 56.4	17.95 ± 14.7	22.3 ± 15.1
Fibrinogen (mg/ml)	6.24 ± 1.53	6.32 ± 1.55	6.96 ± 1.48	5.74 ± 1.48	6.45 ± 3.29	5.531 ± 1.35
D-dimer (ng/ml)	716.8 ± 174.1	456.3 ± 214.1*	1,260.4 ± 328.4**	716 ± 207.1†‡	1,037 ± 188.9*	990.3 ± 160.9‡‡
Cytokines (pg/ml)						
IL-1	3,261.3 ± 789.3	2,988.8 ± 1,161.4	3,090 ± 195.1	3,242.2 ± 539.8	3,135.6 ± 745.2	3,449.8 ± 1,351.3
IL-1	980.4 ± 109.3	858.7 ± 165.7	833.7 ± 59.2	1,150.2 ± 87.2	1,052 ± 254.6	732.3 ± 236.7
IL-2	75.5 ± 7.7	79.6 ± 16.6	73.3 ± 17.1	79.2 ± 6.7	74.9 ± 10.1	62.9 ± 31.6
IL-3	ND	ND	ND	ND	ND	ND
IL-4	31 ± 11	15.2 ± 3.4	28.5 ± 2.9	18.5 ± 1.1	17.9 ± 4.8	14.7 ± 4
IL-5	83 ± 21.7	57.3 ± 21.7	86.3 ± 11.8	83.2 ± 32.5	71.3 ± 21.2	47.9 ± 13.7
IL-6	5,704.5 ± 5,928	4,837.5 ± 7,372.9	2,793.7 ± 1,362.4	41,401.3 ± 19,527.7	4,502.8 ± 6,920.3	1,251.9 ± 1,506.5
IL-9	ND	ND	ND	ND	ND	ND
IL-10	1,917.6 ± 101.2	1,294.2 ± 400.4	2,345.2 ± 270.4	1,349.7 ± 648.9	1,490.9 ± 414.6	1,373.9 ± 433.2
IL-12p40	7,265.9 ± 3,126	3,953.3 ± 3,393.5	3,787.4 ± 357.6	7,288.6 ± 3,178.8	4,772.9 ± 2,716.1	3,783.3 ± 1,895.3
IL-12p70	1,204 ± 329	632.5 ± 210.4	1,381.6 ± 351.1	403.5 ± 95.7	550.4 ± 301.1	567.3 ± 217.6
IL-13	785.7 ± 112	779.2 ± 126.4	945.2 ± 104.1	925.7 ± 88.8	729.4 ± 107.2	594.5 ± 166.3
IL-17	604.6 ± 381	258.5 ± 215.5	306.5 ± 58.8	1,034.8 ± 605.5	320.8 ± 174.1	162 ± 50.2
Eotaxin	12,544.5 ± 233.9	10,914.8 ± 926.4	12,143.5 ± 1,725.8	15,926.5 ± 4,153.5	13,351.3 ± 4,528.1	9,443.4 ± 3,330.1
G-CSF	50,353.8 ± 17,461	31,136.9 ± 14,942.3	30,337.8 ± 6,523	23,835.3 ± 4,648.2	18,890 ± 1,421.9	17,847.2 ± 6,046
GM-CSF	471.5 ± 117.1	280.8 ± 52.8	516.7 ± 15.8	266.1 ± 28.9	299.3 ± 98.6	237.7 ± 71.7
IFN-	366.4 ± 88.1	250.6 ± 59.7	420.4 ± 37.2	329.8 ± 154	339.6 ± 124.1	257.1 ± 72.2
KC	7,457.5 ± 2,541.7	2,551.8 ± 2,653.5	5,664.1 ± 1,218.4	5,741.3 ± 785.7	4,108.6 ± 1,099.6	2,254.1 ± 1,253.1
MCP-1	13,354 ± 15,028.3	9,491.4 ± 11,352.3	5,230.9 ± 364.6	39,269.2 ± 18,129.5	8,778.3 ± 9,132.8	3,283.3 ± 180.7
MIP-1	2,164.7 ± 195.4	1,924.6 ± 558.1	2,327.4 ± 350.4	1,788 ± 356.7	1,783.8 ± 91	1,592.6 ± 350.3
MIP-1	678.1 ± 229.3	567.1 ± 155.1	467.9 ± 12.3	673.1 ± 111.4	465.8 ± 54.4	388.6 ± 72.5
RANTES	5,164.5 ± 2,037.4	4,841 ± 1,885.5	4,447.2 ± 281.1	6,159.7 ± 1,094.2	6,355 ± 3,581.8	2,672.5 ± 950.6
TNF-α	5,917.6 ± 1,712.2	4,323.7 ± 1,546.7	5,536.8 ± 560.1	4,788.7 ± 874.5	3,706.4 ± 753.6	3,887.9 ± 535.8
Blood cell counts (% and 10 <sup>3</sup> /μl)						
Lymphocytes	20.9 ± 7.4/1.9 ± 0.82	27.2 ± 8.5/0.67 ± 0.59	24.1 ± 2.1/0.86 ± 0.48	26.9 ± 4/1.35 ± 0.8	27.1 ± 6.3/0.5 ± 0.3	24.6 ± 8.4/0.93 ± 1.33
Monocytes	7.1 ± 0.9/0.37 ± 0.22	7.2 ± 0.6/0.2 ± 0.15	6.7 ± 0.4/0.21 ± 0.11	7.5 ± 0.9/0.33 ± 0.21	7.9 ± 2/0.1 ± 0.21	6.1 ± 1.3/0.25 ± 0.42
Granulocytes	72 ± 8.2/1.32 ± 0.41	65.5 ± 9/2.25 ± 1	69.2 ± 2.4/2.3 ± 0.56	65.6 ± 4/3.4 ± 1.52	64.9 ± 8.4/1.69 ± 0.7	69.3 ± 9.3/2.57 ± 3.4

All collections were performed at 24 h after LPS challenge/APC treatment. No significant difference was observed between cytokine groups after multivariate testing. \*, P ≤ 0.05; and \*\*, P ≤ 0.01 compared with LPS-challenged mice. ‡, P ≤ 0.05; and ‡‡, P ≤ 0.01 compared with WT LPS/APC mice. †, P ≤ 0.05 compared with EPCR/LPS-challenged mice. The Student's *t* test was used. ND, no detection.